| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFITM3 |
| Uniprot No | Q01628 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-133aa |
| 氨基酸序列 | MNHTVQTFFSPVNSGQPPNYEMLKEEHEVAVLGAPHNPAPPTSTVIHIRS ETSVPDHVVWSLFNTLFMNPCCLGFIAFAYSVKSRDRKMVGDVTGAQAYA STAKCLNIWALILGILMTILLIVIPVLIFQAYG |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFITM3重组蛋白的3篇代表性文献示例(注：文献为虚构示例，仅用于演示格式)：
1. **文献名称**: "IFITM3 Recombinant Protein Inhibits Influenza Virus Entry by Blocking Hemifusion"
**作者**: Smith A et al.
**摘要**: 研究通过大肠杆菌表达系统获得重组IFITM3蛋白，证实其通过阻断病毒膜与宿主细胞膜的半融合过程，抑制甲型流感病毒入侵。
2. **文献名称**: "Antiviral Activity of Recombinant IFITM3 Variants Against SARS-CoV-2"
**作者**: Lee B et al.
**摘要**: 利用哺乳动物细胞表达纯化的IFITM3重组蛋白，发现其N端糖基化修饰对抑制新冠病毒刺突蛋白介导的膜融合具有关键作用。
3. **文献名称**: "Functional Characterization of Recombinant IFITM3 in HIV-1 Restriction"
**作者**: Zhang C et al.
**摘要**: 通过体外实验证明重组IFITM3蛋白可干扰HIV-1病毒囊泡在细胞内的运输，降低病毒基因组释放效率，揭示其广谱抗病毒机制。
(提示：实际文献需通过PubMed/Google Scholar等平台检索关键词“IFITM3 recombinant protein”或“recombinant IFITM3 expression”获取。)
Interferon-induced transmembrane protein 3 (IFITM3) is a key antiviral restriction factor belonging to the IFITM family, which is broadly expressed in response to interferon signaling. It plays a critical role in innate immunity by inhibiting the entry of diverse enveloped viruses, including influenza, dengue, Ebola, and SARS-CoV-2. IFITM3 achieves this by altering membrane fluidity and cholesterol homeostasis, thereby disrupting viral fusion with host cell membranes. Its importance is highlighted by studies linking IFITM3 genetic variants to increased susceptibility to severe viral infections in humans.
Recombinant IFITM3 protein is produced via molecular cloning and expression systems (e.g., E. coli, mammalian cells) to study its structure, function, and therapeutic potential. Purified recombinant IFITM3 retains its antiviral activity and enables in vitro investigations into its interaction with viral components, host membranes, and co-factors. Researchers utilize it to map functional domains, such as the conserved intracellular loop and amphipathic helix, which are essential for membrane localization and antiviral activity. It also aids in exploring post-translational modifications (e.g., palmitoylation) that regulate its trafficking and antiviral efficacy.
Challenges in producing functional recombinant IFITM3 include maintaining proper folding and membrane-associated properties, often requiring detergent solubilization or liposome reconstitution. Despite this, recombinant IFITM3 remains a vital tool for developing broad-spectrum antivirals, understanding viral resistance mechanisms, and designing immunotherapies. Its role in modulating immune responses and inflammation further underscores its relevance in infectious disease and oncology research.
×
